Comment on“Clinical outcomes and histologic findings of patients with hepatocellular carcinoma with durable partial response or durable stable disease after receiving atezolizumab plus bevacizumab”  

作　　者：Binghua Li Qiang Wang Weiwei Hu Huan Li Peng Yan Yajuan Cao Decai Yu 

机构地区：[1]Division of Hepatobiliary and Transplantation Surgery,Department of General Surgery,Nanjing Drum Tower Hospital,The Affiliated Hospital of Nanjing University Medical School,Nanjing 210008,China [2]Department of Clinical Science,Intervention and Technology(CLINTEC),Division of Medical Imaging and Technology,Karolinska Institutet,Stockholm 14186,Sweden [3]Center for New Drug Safety Evaluation and Research,State Key Laboratory of Natural Medicines,China Pharmaceutical University,Nanjing 211198,China

出　　处：《iLIVER》2024年第4期64-65,共2页国际肝胆健康(英文)

基　　金：supported by grants from the National Natural Science Foundation of China(Nos.82372834 and 82173129);the Jiangsu Outstanding Youth Foundation(BK20240119).

摘　　要：We read with great interest the recent article by Shen et al.[1],which provides valuable insights into the outcomes and histopathologic characteristics of hepatocellular carcinoma(HCC)patients treated with atezolizumab plus bevacizumab(Atezo-Bev),particularly those demonstrating a durable partial response(PR)or stable disease(SD).The authors claimed no reliable radiologic features or blood-based biomarker to predict pathologic complete response(PCR)of the residual tumors.

关 键 词：(PCR) PATIENTS HEPATOCELLULAR 

分 类 号：R73[医药卫生—肿瘤]